Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10512363rdf:typepubmed:Citationlld:pubmed
pubmed-article:10512363lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:10512363lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:10512363lifeskim:mentionsumls-concept:C0013682lld:lifeskim
pubmed-article:10512363lifeskim:mentionsumls-concept:C0392756lld:lifeskim
pubmed-article:10512363lifeskim:mentionsumls-concept:C1256369lld:lifeskim
pubmed-article:10512363lifeskim:mentionsumls-concept:C0205349lld:lifeskim
pubmed-article:10512363pubmed:issue10lld:pubmed
pubmed-article:10512363pubmed:dateCreated1999-10-19lld:pubmed
pubmed-article:10512363pubmed:abstractTextRecent studies have shown that genetic deficiency of the adipocyte fatty acid-binding protein (aP2) results in minor alterations of plasma lipids and adipocyte development but provides significant protection from dietary obesity-induced hyperinsulinemia and insulin resistance. To identify potential mechanisms responsible for this phenotype, we examined lipolysis and insulin secretion in aP2-/- mice. Beta-adrenergic stimulation resulted in a blunted rise of blood glycerol levels in aP2-/- compared with aP2+/+ mice, suggesting diminished lipolysis in aP2-/- adipocytes. Confirming this, primary adipocytes isolated from aP2-/- mice showed attenuated glycerol and free fatty acid (FFA) release in response to dibutyryl cAMP. The decreased lipolytic response seen in the aP2-/- mice was not associated with altered expression levels of hormone-sensitive lipase or perilipin. The acute insulin secretory response to beta-adrenergic stimulation was also profoundly suppressed in aP2-/- mice despite comparable total concentrations and only minor changes in the composition of systemic FFAs. To address whether levels of specific fatty acids are different in aP2-/- mice, the plasma FFA profile after beta-adrenergic stimulation was determined. Significant reduction in both stearic and cis-11-eicoseneic acids and an increase in palmitoleic acid were observed. The response of aP2-/- mice to other insulin secretagogues such as arginine and glyburide was similar to that of aP2+/+ mice, arguing against generally impaired function of pancreatic beta-cells. Finally, no aP2 expression was detected in isolated pancreatic islet cells. These results provide support for the existence of an adipo-pancreatic axis, the proper action of which relies on the presence of aP2. Consequently, aP2's role in the pathogenesis of type 2 diabetes might involve regulation of both hyperinsulinemia and insulin resistance through its impact on both lipolysis and insulin secretion.lld:pubmed
pubmed-article:10512363pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10512363pubmed:languageenglld:pubmed
pubmed-article:10512363pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10512363pubmed:citationSubsetAIMlld:pubmed
pubmed-article:10512363pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10512363pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10512363pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10512363pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10512363pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10512363pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10512363pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10512363pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10512363pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10512363pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10512363pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10512363pubmed:statusMEDLINElld:pubmed
pubmed-article:10512363pubmed:monthOctlld:pubmed
pubmed-article:10512363pubmed:issn0012-1797lld:pubmed
pubmed-article:10512363pubmed:authorpubmed-author:MorganMMlld:pubmed
pubmed-article:10512363pubmed:authorpubmed-author:MeyersD SDSlld:pubmed
pubmed-article:10512363pubmed:authorpubmed-author:ParkerR ARAlld:pubmed
pubmed-article:10512363pubmed:authorpubmed-author:MakowskiLLlld:pubmed
pubmed-article:10512363pubmed:authorpubmed-author:HotamisligilG...lld:pubmed
pubmed-article:10512363pubmed:authorpubmed-author:SchejaLLlld:pubmed
pubmed-article:10512363pubmed:authorpubmed-author:UysalK TKTlld:pubmed
pubmed-article:10512363pubmed:authorpubmed-author:WiesbrockS...lld:pubmed
pubmed-article:10512363pubmed:authorpubmed-author:ShimshekD RDRlld:pubmed
pubmed-article:10512363pubmed:issnTypePrintlld:pubmed
pubmed-article:10512363pubmed:volume48lld:pubmed
pubmed-article:10512363pubmed:ownerNLMlld:pubmed
pubmed-article:10512363pubmed:authorsCompleteYlld:pubmed
pubmed-article:10512363pubmed:pagination1987-94lld:pubmed
pubmed-article:10512363pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:10512363pubmed:meshHeadingpubmed-meshheading:10512363...lld:pubmed
pubmed-article:10512363pubmed:meshHeadingpubmed-meshheading:10512363...lld:pubmed
pubmed-article:10512363pubmed:meshHeadingpubmed-meshheading:10512363...lld:pubmed
pubmed-article:10512363pubmed:meshHeadingpubmed-meshheading:10512363...lld:pubmed
pubmed-article:10512363pubmed:meshHeadingpubmed-meshheading:10512363...lld:pubmed
pubmed-article:10512363pubmed:meshHeadingpubmed-meshheading:10512363...lld:pubmed
pubmed-article:10512363pubmed:meshHeadingpubmed-meshheading:10512363...lld:pubmed
pubmed-article:10512363pubmed:meshHeadingpubmed-meshheading:10512363...lld:pubmed
pubmed-article:10512363pubmed:meshHeadingpubmed-meshheading:10512363...lld:pubmed
pubmed-article:10512363pubmed:meshHeadingpubmed-meshheading:10512363...lld:pubmed
pubmed-article:10512363pubmed:meshHeadingpubmed-meshheading:10512363...lld:pubmed
pubmed-article:10512363pubmed:meshHeadingpubmed-meshheading:10512363...lld:pubmed
pubmed-article:10512363pubmed:meshHeadingpubmed-meshheading:10512363...lld:pubmed
pubmed-article:10512363pubmed:meshHeadingpubmed-meshheading:10512363...lld:pubmed
pubmed-article:10512363pubmed:meshHeadingpubmed-meshheading:10512363...lld:pubmed
pubmed-article:10512363pubmed:meshHeadingpubmed-meshheading:10512363...lld:pubmed
pubmed-article:10512363pubmed:meshHeadingpubmed-meshheading:10512363...lld:pubmed
pubmed-article:10512363pubmed:year1999lld:pubmed
pubmed-article:10512363pubmed:articleTitleAltered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice.lld:pubmed
pubmed-article:10512363pubmed:affiliationDepartment of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA.lld:pubmed
pubmed-article:10512363pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10512363pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:10512363pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:11770entrezgene:pubmedpubmed-article:10512363lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10512363lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10512363lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10512363lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10512363lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10512363lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10512363lld:pubmed